Portage Biotech Regains Full Compliance with Nasdaq Continued Listing Requirements
Portage Biotech (NASDAQ: PRTG), a clinical-stage immuno-oncology company, has received formal notice from Nasdaq confirming its full compliance with all continued listing requirements for The Nasdaq Capital Market as of June 24, 2025. This notification marks an important milestone for the company in maintaining its position on the Nasdaq exchange.
Portage Biotech (NASDAQ: PRTG), un'azienda immuno-oncologica in fase clinica, ha ricevuto una comunicazione ufficiale da Nasdaq che conferma la piena conformità a tutti i requisiti di quotazione continuativa per il Nasdaq Capital Market a partire dal 24 giugno 2025. Questa notifica rappresenta un traguardo importante per l'azienda nel mantenere la sua posizione sulla borsa Nasdaq.
Portage Biotech (NASDAQ: PRTG), una compañía de inmuno-oncología en etapa clínica, ha recibido una notificación formal de Nasdaq que confirma su total cumplimiento con todos los requisitos continuos de listado para el Nasdaq Capital Market a partir del 24 de junio de 2025. Esta notificación representa un hito importante para la empresa en mantener su posición en la bolsa Nasdaq.
Portage Biotech (NASDAQ: PRTG)는 임상 단계의 면역종양학 회사로서, 2025년 6월 24일부로 Nasdaq Capital Market의 모든 상장 유지 요건을 완전히 충족했다는 Nasdaq의 공식 통지를 받았습니다. 이 통지는 회사가 Nasdaq 거래소에서의 위치를 유지하는 데 있어 중요한 이정표입니다.
Portage Biotech (NASDAQ : PRTG), une société d'immuno-oncologie en phase clinique, a reçu une notification officielle de Nasdaq confirmant sa conformité totale à toutes les exigences de maintien de la cotation pour le Nasdaq Capital Market à compter du 24 juin 2025. Cette notification constitue une étape importante pour l'entreprise afin de conserver sa position sur la bourse Nasdaq.
Portage Biotech (NASDAQ: PRTG), ein Immunonkologie-Unternehmen in der klinischen Phase, hat eine offizielle Benachrichtigung von Nasdaq erhalten, die die vollständige Einhaltung aller fortlaufenden Notierungsanforderungen für den Nasdaq Capital Market zum 24. Juni 2025 bestätigt. Diese Mitteilung stellt einen wichtigen Meilenstein für das Unternehmen dar, um seine Position an der Nasdaq-Börse zu sichern.
- Regained full compliance with Nasdaq listing requirements
- Maintained listing on Nasdaq Capital Market
- None.
DOVER, Del., June 25, 2025 (GLOBE NEWSWIRE) -- Portage Biotech Inc. (“Portage” or the “Company”) (NASDAQ: PRTG), a clinical-stage immuno-oncology company formed under the laws of the British Virgin Islands (“Portage”), announced today that on June 24, 2025, the Company received formal notice from The Nasdaq Stock Market LLC that the Company has evidenced compliance with all applicable requirements for continued listing on The Nasdaq Capital Market.
About Portage Biotech
Portage Biotech is a clinical-stage immuno-oncology company advancing a pipeline of novel biologics to transform the immune system’s ability to fight cancer. For more information, visit www.portagebiotech.com.
Forward-Looking Statements
All statements in this news release, other than statements of historical facts, including without limitation, statements regarding the Company’s business strategy, plans and objectives of management for future operations and those statements preceded by, followed by or that otherwise include the words “believe,” “expects,” “anticipates,” “intends,” “estimates,” “will,” “may,” “plans,” “potential,” “continues,” or similar expressions or variations on such expressions are forward-looking statements. As a result, forward-looking statements are subject to certain risks and uncertainties, including, but not limited to: the risk that the Company may not secure financing, the uncertainty of the Company’s ability to continue as a going concern, scientific results may not be as expected, and other factors set forth in “Item 3 - Key Information-Risk Factors” in the Company’s Annual Report on Form 20-F for the year ended March 31, 2024 and “Business Environment – Risk Factors” in the Company’s Management’s Discussion and Analysis for the Three and Six Months ended September 30, 2024, filed as Exhibit 99.2 to the Company’s Form 6-K. Although the Company believes that the expectations reflected in these forward-looking statements are reasonable, undue reliance should not be placed on them as actual results may differ materially from these forward-looking statements. The forward-looking statements contained in this news release are made as of the date hereof, and the Company undertakes no obligation to update publicly or revise any forward-looking statements or information, except as required by law.
For More Information:
Portage Biotech
Alexander Pickett, Chief Executive Officer
ir@portagebiotech.com
FAQ
What did Portage Biotech (PRTG) announce regarding Nasdaq compliance on June 24, 2025?
Why was Portage Biotech (PRTG) facing Nasdaq listing compliance issues?
What is Portage Biotech's (PRTG) current listing status on Nasdaq?
What type of company is Portage Biotech (PRTG)?
